August 30, 2014 11:52 PM ET

Biotechnology

Company Overview of Eagle Pharmaceuticals Inc.

Company Overview

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexe...

50 Tice Boulevard

Suite 315

Woodcliff Lake, NJ 07677

United States

Founded in 2007

28 Employees

Phone:

201-326-5300

Key Executives for Eagle Pharmaceuticals Inc.

Chief Executive Officer
Age: 54
Total Annual Compensation: $408.0K
Chief Medical Officer and Head of Research & Development
Age: 55
Total Annual Compensation: $303.8K
Chief Scientific Officer
Age: 55
Total Annual Compensation: $272.6K
Compensation as of Fiscal Year 2013.

Eagle Pharmaceuticals Inc. Key Developments

Eagle Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014

Eagle Pharmaceuticals Inc. reported unaudited earnings results for the third quarter and nine months ended June 30, 2014. For the quarter, the company's total revenue was $5,791,876 compared to $5,075,029 a year ago. Loss from operations was $2,982,398 compared to income from operations $1,259,751 a year ago. Loss before income tax benefit was $2,934,079 compared to income before income tax benefit of $754,576 a year ago. Net loss attributable to common stockholders was $2,934,079 compared to net income attributable to common stockholders of $320,061 a year ago. Loss per share attributable to common stockholders basic and diluted was $0.21 compared to income per share attributable to common stockholders basic and diluted of $0.11 a year ago. For the nine months, the company's total revenue was $16,288,207 compared to $9,038,929 a year ago. Loss from operations was $9,650,868 compared to $5,923,839 a year ago. Loss before income tax benefit was $10,168,457 compared to $7,430,505 a year ago. Net loss attributable to common stockholders was $10,539,615 compared to $9,236,369 a year ago. Loss per share attributable to common stockholders basic and diluted was $1.23 compared to $3.06 a year ago.

Eagle Pharmaceuticals Inc. to Report Q3, 2014 Results on Aug 11, 2014

Eagle Pharmaceuticals Inc. announced that they will report Q3, 2014 results Pre-Market on Aug 11, 2014

Eagle Pharmaceuticals Inc., Q3 2014 Earnings Call, Aug 11, 2014

Eagle Pharmaceuticals Inc., Q3 2014 Earnings Call, Aug 11, 2014

Similar Private Companies By Industry

Company Name Region
NKT Therapeutics, Inc. United States
Nimbus Discovery, LLC United States
RGO Bioscience LLC United States
Enobia Canada Limited Partnership United States
BioResource International, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eagle Pharmaceuticals Inc., please visit www.eagleus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.